Direct oral anticoagulants (DOACs)

被引：9
|
作者：
Vazquez, Sara [1 ]
Rondina, Matthew T. [2 ,3 ,4 ]
机构：
[1] Univ Utah, Hlth Sci Ctr, Univ Healthcare Thrombosis Serv, Salt Lake City, UT USA
[2] Univ Utah, Dept Internal Med, Div Gen Internal Med, Salt Lake City, UT 84112 USA
[3] Univ Utah, Sch Med, Program Mol Med, Salt Lake City, UT USA
[4] George E Wahlen Salt Lake City VAMC, Dept Internal Med, Salt Lake City, UT USA
来源：
VASCULAR MEDICINE | 2015年 / 20卷 / 06期
关键词：
anticoagulants; apixaban; dabigatran; edoxaban; rivaroxaban; thrombosis; DVT; pulmonary embolism; PATIENT;
D O I：
10.1177/1358863X15600256
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
DOACs are a new group of blood-thinner medications that may have some advantages over warfarin. A health care provider will look at several different factors to help patients decide if a DOAC is a good choice. Patients taking DOACs should discuss medication changes, a plan for taking the DOAC before and after a surgery, and any bleeding side effects with their health care provider.
引用
收藏
页码：575 / 577
页数：3
相关论文
共 50 条
  • [21] Challenges to Laboratory Monitoring of Direct Oral Anticoagulants
    Qiao, Jesse
    Tran, Minh-Ha
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [22] Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
    Gustavo Guimarães Moreira Balbi
    Marcelo de Souza Pacheco
    Odirlei Andre Monticielo
    Andreas Funke
    Adriana Danowski
    Mittermayer Barreto Santiago
    Henrique Luiz Staub
    Jozelia Rêgo
    Danieli Castro Oliveira de Andrade
    Advances in Rheumatology, 60
  • [23] Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS)
    Moreira Balbi, Gustavo Guimaraes
    Pacheco, Marcelo de Souza
    Monticielo, Odirlei Andre
    Funke, Andreas
    Danowski, Adriana
    Santiago, Mittermayer Barreto
    Staub, Henrique Luiz
    Rego, Jozelia
    Oliveira de Andrade, Danieli Castro
    ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)
  • [24] Management of bleeding in patients treated with direct oral anticoagulants
    Levi, Marcel
    CRITICAL CARE, 2016, 20
  • [25] Management of bleeding in patients treated with direct oral anticoagulants
    Marcel Levi
    Critical Care, 20
  • [26] Ten things ICU specialists need to know about direct oral anticoagulants (DOACs)
    Stensballe, Jakob
    Moller, Morten Hylander
    INTENSIVE CARE MEDICINE, 2019, 45 (01) : 89 - 92
  • [27] Potential Role of Direct Oral Anticoagulants in the Management of Heparin-induced Thrombocytopenia
    Barlow, Ashley
    Barlow, Brooke
    Reinaker, Travis
    Harris, Justin
    PHARMACOTHERAPY, 2019, 39 (08): : 837 - 853
  • [28] Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective
    Federica Ranzato
    Roberta Roberti
    Cristina Deluca
    Mariarosa Carta
    Alessia Peretti
    Diana Polo
    Francesco Perini
    Emilio Russo
    Gianfranco Di Gennaro
    Neurological Sciences, 2024, 45 : 277 - 288
  • [29] Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective
    Ranzato, Federica
    Roberti, Roberta
    Deluca, Cristina
    Carta, Mariarosa
    Peretti, Alessia
    Polo, Diana
    Perini, Francesco
    Russo, Emilio
    Di Gennaro, Gianfranco
    NEUROLOGICAL SCIENCES, 2024, 45 (01) : 277 - 288
  • [30] Direct oral anticoagulants
    Bouvenot, Gilles
    Bounhoure, Jean-Paul
    Montastruc, Jean-Louis
    Vacheron, Andre
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (06): : 1157 - 1195
12345